Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

Taiwan · Delayed Price · Currency is TWD

117.00

-6.50 (-5.26%)

At close: Nov 6, 2026

Market Cap	15.71B
Revenue (ttm)	113.34M +10,946.9%
Net Income	-155.83M
EPS	-1.17
Shares Out	134.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	680,138
Open	121.50
Previous Close	123.50
Day's Range	105.00 - 122.00
52-Week Range	37.55 - 185.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About TPEX:7871

Elixiron Immunotherapeutics (Cayman) Limited engages in the development of immunotherapies for cancer and immune diseases in the United States. It develops EI-1071, a small molecule inhibitor of CSF-1R used for the treatment of Alzheimer's disease and amyotrophic lateral sclerosis; EI-001 for the treatment of vitiligo and hemophagocytic lymphohistiocytosis (HLH); and EI-012, a monoclonal antibody and EI-220 mRNA for the treatment of cancer. It also offers mRNA drug development platform, which focuses on in-vivo expression of biologics, accelera... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2017

Country Cayman Islands

Stock Exchange Taipei Exchange

Ticker Symbol 7871

Full Company Profile

Financial Performance

In 2025, TPEX:7871's revenue was 50.29 million, an increase of 6162.39% compared to the previous year's 803,000. Losses were -1.11 billion, 151.3% more than in 2024.

Financial Statements